I-Mab Biopharma (IMAB) Receives Nasdaq Non-compliance Notice
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
March 21, 2025 4:30 PM EDTROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), announced today that on March 19, 2025 it received a written notice (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement under the Nasdaq Listing Rules (the Listing Rules). Based on the closing bid price of the Companys listed securities for the period from February 3, 2025 to March 18, 2025, the Company has not met the minimum bid price requirement set forth in Listing Rule 5450(a)(1) during... More
